Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNFα

Abstract

The most limiting factor regarding the use of TNFα in tumour therapy is systemic toxicity. The expression of membrane-bound (nonsecreted) TNFα within a tumour may serve to reduce systemic toxicity while retaining antitumour activity. Two adenovirus (Ad) vectors were constructed: (1) Ad-mTNF-wt expressing wild-type murine TNFα; and (2) Ad-mTNF-MEM expressing a mutant nonsecreted (membrane-bound) form. Only the Ad-mTNF-wt vector induced high levels of TNFα secretion in transduced cells (approximately 400 ng/10 6 cells), however, both vectors induced efficient cell surface expression as detected by FACS. These vectors were used in tumour immunotherapy trials in a murine transgenic breast cancer model. High serum concentrations of mTNFα (approximately 1 ng/ml) were detected only in Ad-mTNF-wt-treated mice, while both vectors induced substantial disruption of tumour pathology. The wt TNF vector was highly toxic, killing 12 of 16 mice at a dose of 5 × 108 p.f.u., whereas the Ad-mTNF-MEM vector showed low toxicity killing three of 27 at the same dose. Both vectors induced partial, and in some cases, permanent tumour regressions, with cured mice displaying protective immunity and specific CTL activity against the tumour. These results indicate that the use of a nonsecreted form of TNFα can result in a relatively large reduction in systemic toxicity with little or no reduction in antitumour activity.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marr, R., Addison, C., Snider, D. et al. Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNFα. Gene Ther 4, 1181–1188 (1997). https://doi.org/10.1038/sj.gt.3300528

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3300528

Keywords

This article is cited by

Search

Quick links